MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|HER2 Positive Breast Cancer
Interventions: DRUG: MM-302|DRUG: Gemcitabine|DRUG: Capecitabine|DRUG: Vinorelbine|DRUG: Trastuzumab
Sponsor: Merrimack Pharmaceuticals